Bavarian Nordic has received Health Canada approval for VIMKUNYA, a single-dose vaccine protecting against chikungunya virus for individuals aged 12 and older. The virus-like particle vaccine is the first of its kind approved in Canada for the mosquito-borne disease. This marks VIMKUNYA's fifth regulatory approval, following clearances from the US FDA, European Commission, UK MHRA and Swissmedic. The vaccine is designed to induce protective immunity within one week of vaccination and does not contain viral genetic material. Chikungunya has been identified in over 110 countries and causes severe joint pain, with 30-40% of patients developing chronic symptoms lasting months or years. In 2025, more than 500,000 cases and nearly 200 deaths were reported worldwide, though experts believe the disease is severely underreported.

Bavarian Nordic reported revenue of DKK 1,058 million for the first quarter of 2026, with its Travel Health business growing 14% year-on-year to DKK 721 million, driven by increased rabies vaccine demand and its chikungunya vaccine launch. Public Preparedness revenue fell 53% to DKK 294 million, reflecting normalised mpox outbreak conditions. The Danish biotech company achieved an EBITDA of DKK 165 million, representing a 16% margin. It maintained its upgraded full-year guidance of DKK 5,500–5,700 million revenue and approximately 28% EBITDA margin. Key developments included launching the chikungunya vaccine in Benelux countries, securing distribution agreements in Brazil and India, and submitting data to extend its mpox vaccine approval to children aged 2–11 years. CEO Paul Chaplin announced plans to step down by year-end.

Bavarian Nordic awarded contract options from the U.S. Government for production and supply of freeze-dried smallpox vaccines. * Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines. * Company upgrades full-year financial guidance COPENHAGEN, Denmark, May 11, 2026 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS(R) smallpox vaccine. The options will support the manufacturing and supply of freeze-dried JYNNEOS, including manufacturing of additional bulk vaccine necessary for fulfilling the contract, as well as supplemental payments, triggered by the demonstration of an extended shelf-life. These options secure the remaining doses under the original order for 11.5 million doses, and the freeze-dried doses will be manufactured and delivered during 2027. The order for bulk vaccine, which represents the majority of the contract value, is to replace the bulk consumed for liquid-frozen doses supplied to BARDA during the monkeypox outbreak in 2022/23. The vaccine bulk will be invoiced during 2026, and combined with other recent, minor orders, Bavarian Nordic has now secured contracts in the Public Preparedness business in 2026 of approximately DKK 2,000 million, an increase of approximately DKK 600 million compared to the level previously announced. Following this, the Company raises its expectations for the Public Preparedness business in 2026 to revenue of DKK 2,300 - 2,500 million, leading to an upgrade of the overall guidance for 2026. Total revenue of DKK 5,500 - 5,700 million is now expected and the EBITDA margin is expected to reach approximately 28%. See also table below. Paul Chaplin, President & CEO of Bavarian Nordic, said: "The latest order is a significant milestone in our long standing private-public partnership with the U.S. Government. Almost 10 years ago we started a program together with BARDA to develop a new formulation that would improve the storage and transportation logistics for this vaccine, further improving the preparedness and protection of U.S. citizens. This has seen a freeze-dried smallpox vaccine formulation developed, approved, and next year we will deliver the remaining doses for the 11.5 million order, demonstrating what a strong private-public partnership can achieve in terms of protecting lives from emerging diseases and biological threats." About its contracts with the U.S. government For more than two decades, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine, JYNNEOS(R), to ensure all populations can be protected from smallpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. The vaccine was initially developed as a liquid-frozen formulation and was approved by the FDA in 2019. It is the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research, development, procurement, and availability of medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) threats through public-private partnerships. Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for procurement since 2010 and in response to the monkeypox outbreak in 2022-2023. BARDA has supported the development of a freeze-dried formulation of the vaccine and in 2017 awarded the Company a ten-year contract, covering development and manufacturing to replenish doses. The freeze-dried formulation of JYNNEOS, approved by the FDA in March 2025, provides certain advantages over the liquid-frozen formulation in terms of transportation, storage conditions and shelf life, all of which are important factors for long-term storage. To support this endeavour, Bavarian Nordic invested in a commercial manufacturing facility. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201700019C. 2026 upgraded financial guidance | DKK million | Former FY 2026 guidance | New FY 2026 guidance | | Revenue | 5,000 - 5,200 | 5,500 - 5,700 | | Travel Health | ~3,000 | ~3,000 | | Public Preparedness | 1,800 - 2,000 | 2,300 - 2,500 | | Other revenue | 200 | 200 | | EBITDA margin | 25% | ~28% | About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. Bavarian Nordic Group is a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of its control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning its plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Bavarian Nordic Group undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, [email protected] US: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, [email protected], Tel: +45 53 88 06 03 Company Announcement no. 23 / 2026 Published on May 11, 2026, 18:30 CET